Payment overview · 2025
General Payments
$105,565.30
350 reported records · 36 companies
Healthcare provider profile · identity verified
Christopher C Laganke, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · CULLMAN, AL · NPI 1811931546
Verified facts
What the public records show
CMS Open Payments records show Christopher C Laganke, MD received $105,565.30 in general payments during 2025 across 350 reported records.
EMD Serono, Inc. accounted for 66.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Fycompa, Mavenclad, Nuplazid, Nurtec Odt, Qulipta, Sunosi, Tascenso Odt, Tysabri, Ubrelvy, Valtoco, Vumerity, Zeposia, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuplazid by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Auvelity by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Sunosi by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Fycompa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 9581 records involving 2490 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Zeposia by this doctor in 2024.
Cycle Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tascenso ODT as an associated drug or biological on 1624 records involving 1040 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Tascenso Odt by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZEPOSIA as an associated drug or biological on 976 records involving 466 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Zeposia by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Mavenclad as an associated drug or biological on 3542 records involving 766 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mavenclad by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gocovri by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Ampyra by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Valtoco by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Mayzent by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ztlido by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Gammagard Liquid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trintellix by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $70,286.50 | 66.6% | 41 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19,545.20 | 18.5% | 30 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $11,653.66 | 11.0% | 22 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $685.36 | 0.7% | 73 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $301.29 | 0.3% | 17 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $290.00 | 0.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $264.60 | 0.2% | 11 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $236.90 | 0.2% | 10 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$205.00 | 0.2% | 9 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $204.42 | 0.2% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $200.74 | 0.2% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $186.29 | 0.2% | 12 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $181.89 | 0.2% | 10 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $153.90 | 0.1% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $140.00 | 0.1% | 8 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $100.93 | 0.1% | 27 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.13 | 0.1% | 4 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $81.06 | 0.1% | 5 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $79.42 | 0.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.48 | 0.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.13 | 0.1% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $64.55 | 0.1% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$58.20 | 0.1% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $49.94 | 0.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.05 | 0.1% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $45.98 | 0.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.14 | 0.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $42.61 | 0.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $34.72 | 0.0% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $24.54 | 0.0% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $21.87 | 0.0% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.12 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.12 | 0.0% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.27 | 0.0% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $15.34 | 0.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.95 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,932.50 | 15 |
| Consulting Fee | $48,230.50 | 5 |
| Food and Beverage | $5,291.91 | 322 |
| Travel and Lodging | $2,095.44 | 7 |
| Education | $14.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $69,424.27 | 12 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $14,944.62 | 23 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $11,653.66 | 22 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $4,739.79 | 18 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $596.31 | 67 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $301.29 | 17 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $236.90 | 10 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $205.00 | 9 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $204.42 | 12 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $187.29 | 15 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $181.89 | 10 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $153.90 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $126.80 | 7 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $121.90 | 7 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $100.93 | 27 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $98.13 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $78.47 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $76.48 | 4 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $65.47 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $64.55 | 4 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $62.20 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $59.49 | 5 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $52.70 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $49.94 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $46.76 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $45.98 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.14 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $42.61 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $36.35 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $33.82 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 79 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Mavenclad mavenclad |
2025 | Mavenclad | 2024 | 28 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 263 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 305 | exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tascenso ODT tascenso odt |
2025 | Tascenso Odt | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 294 | exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZEPOSIA zeposia |
2025 | Zeposia | 2024 | 200 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
190 | 49 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
305 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
294 | 55 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
127 | 23 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 9581 supporting records · 2490 recipient NPIs · example record 1184377823 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
200 | 25 |
| Cycle Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Tascenso ODT open payments reported associated product |
CMS Open Payments — General Payments 1624 supporting records · 1040 recipient NPIs · example record 1248898756 |
Tascenso Odt · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ZEPOSIA open payments reported associated product |
CMS Open Payments — General Payments 976 supporting records · 466 recipient NPIs · example record 1184381876 |
Zeposia · 2024 Exact normalized brand match · 1 Part D row |
200 | 25 |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Mavenclad open payments reported associated product |
CMS Open Payments — General Payments 3542 supporting records · 766 recipient NPIs · example record 1236867010 |
Mavenclad · 2024 Exact normalized brand match · 1 Part D row |
28 | 15 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
201 | 46 |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
137 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
263 | 65 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 3056 | 397 |
| Baclofen | Baclofen | 2189 | 425 |
| Lacosamide | Lacosamide | 2050 | 361 |
| Alprazolam | Alprazolam | 1565 | 207 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1482 | 160 |
| Clonazepam | Clonazepam | 1433 | 203 |
| Gabapentin | Gabapentin | 1277 | 206 |
| Dalfampridine Er | Dalfampridine | 965 | 159 |
| Tizanidine Hcl | Tizanidine Hcl | 886 | 141 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 815 | 93 |
| Armodafinil | Armodafinil | 752 | 167 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 666 | 102 |
| Primidone | Primidone | 573 | 110 |
| Pregabalin | Pregabalin | 570 | 90 |
| Oxcarbazepine | Oxcarbazepine | 556 | 98 |
| Temazepam | Temazepam | 496 | 78 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 471 | 95 |
| Vyvanse | Lisdexamfetamine Dimesylate | 467 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 450 | 107 |
| Topiramate | Topiramate | 406 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 388 | 51 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 380 | 76 |
| Modafinil | Modafinil | 371 | 72 |
| Fluoxetine Hcl | Fluoxetine Hcl | 369 | 65 |
| Donepezil Hcl | Donepezil Hcl | 352 | 71 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 336 | 58 |
| Bupropion Xl | Bupropion Hcl | 323 | 50 |
| Methylphenidate Hcl | Methylphenidate Hcl | 316 | 48 |
| Tramadol Hcl | Tramadol Hcl | 312 | 47 |
| Qulipta | Atogepant | 305 | 55 |
| Methocarbamol | Methocarbamol | 295 | 57 |
| Ubrelvy | Ubrogepant | 294 | 55 |
| Diazepam | Diazepam | 293 | 74 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 286 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 284 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 274 | 50 |
| Nurtec Odt | Rimegepant Sulfate | 263 | 65 |
| Sertraline Hcl | Sertraline Hcl | 262 | 49 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 260 | 35 |
| Divalproex Sodium Er | Divalproex Sodium | 254 | 52 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 250 | 48 |
| Aripiprazole | Aripiprazole | 244 | 38 |
| Trazodone Hcl | Trazodone Hcl | 241 | 53 |
| Oxycodone Hcl | Oxycodone Hcl | 238 | 25 |
| Buspirone Hcl | Buspirone Hcl | 237 | 43 |
| Teriflunomide | Teriflunomide | 235 | 29 |
| Prednisone | Prednisone | 234 | 168 |
| Ropinirole Hcl | Ropinirole Hcl | 234 | 37 |
| Aimovig Autoinjector | Erenumab-Aooe | 224 | 29 |
| Lamotrigine | Lamotrigine | 218 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 218 | 59 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 216 | 28 |
| Dantrolene Sodium | Dantrolene Sodium | 214 | 31 |
| Sumatriptan Succinate | Sumatriptan Succinate | 212 | 42 |
| Meloxicam | Meloxicam | 210 | 40 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 205 | 47 |
| Rizatriptan | Rizatriptan Benzoate | 204 | 48 |
| Ampyra | Dalfampridine | 201 | 46 |
| Levetiracetam | Levetiracetam | 200 | 31 |
| Zeposia | Ozanimod Hydrochloride | 200 | 25 |
| Memantine Hcl | Memantine Hcl | 198 | 36 |
| Eszopiclone | Eszopiclone | 194 | 34 |
| Linzess | Linaclotide | 190 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 28 |
| Indomethacin Er | Indomethacin | 176 | 33 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 171 | 25 |
| Lidocaine | Lidocaine | 169 | 43 |
| Rexulti | Brexpiprazole | 169 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 163 | 32 |
| Dronabinol | Dronabinol | 153 | 54 |
| Ibuprofen | Ibuprofen | 152 | 33 |
| Omeprazole | Omeprazole | 151 | 28 |
| Methenamine Hippurate | Methenamine Hippurate | 146 | 23 |
| Meclizine Hcl | Meclizine Hcl | 143 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 142 | 33 |
| Myrbetriq | Mirabegron | 140 | 23 |
| Mayzent | Siponimod | 137 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 133 | 19 |
| Promethazine Hcl | Promethazine Hcl | 130 | 29 |
| Vraylar | Cariprazine Hcl | 127 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 122 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 121 | 25 |
| Fluconazole | Fluconazole | 115 | 68 |
| Valacyclovir | Valacyclovir Hcl | 114 | 21 |
| Emgality Pen | Galcanezumab-Gnlm | 113 | 18 |
| Ondansetron Odt | Ondansetron | 111 | 33 |
| Lorazepam | Lorazepam | 109 | 15 |
| Montelukast Sodium | Montelukast Sodium | 109 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 109 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 19 |
| Lisinopril | Lisinopril | 104 | 18 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 98 | 30 |
| Kesimpta Pen | Ofatumumab | 96 | 14 |
| Furosemide | Furosemide | 91 | 17 |
| Neupro | Rotigotine | 91 | 17 |
| Orphenadrine-Aspirin-Caffeine | Orphenadrine/Aspirin/Caffeine | 91 | 18 |
| Tolterodine Tartrate | Tolterodine Tartrate | 91 | 20 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 85 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 84 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 84 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 83 | 11 |
| Oxtellar Xr | Oxcarbazepine | 83 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 80 | suppressed |
| Oxycontin | Oxycodone Hcl | 80 | suppressed |
| Briviact | Brivaracetam | 79 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 78 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 78 | 12 |
| Pilocarpine Hcl | Pilocarpine Hcl | 77 | 14 |
| Indomethacin | Indomethacin | 76 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 15 |
| Lamotrigine Er | Lamotrigine | 75 | 12 |
| Potassium Chloride | Potassium Chloride | 75 | 17 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 74 | 15 |
| Famotidine | Famotidine | 71 | 14 |
| Propranolol Hcl | Propranolol Hcl | 71 | 18 |
| Celecoxib | Celecoxib | 69 | 15 |
| Methimazole | Methimazole | 68 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 11 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 66 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 54 |
| Amantadine | Amantadine Hcl | 65 | 12 |
| Betaseron | Interferon Beta-1b | 64 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 63 | suppressed |
| Acyclovir | Acyclovir | 62 | 30 |
| Aubagio | Teriflunomide | 61 | suppressed |
| Nucynta | Tapentadol Hcl | 61 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 60 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 60 | suppressed |
| Scopolamine | Scopolamine | 58 | 17 |
| Belsomra | Suvorexant | 56 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 46 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 12 |
| Dexamethasone | Dexamethasone | 55 | 46 |
| Metformin Hcl Er | Metformin Hcl | 55 | 11 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Levetiracetam Er | Levetiracetam | 54 | suppressed |
| Quviviq | Daridorexant Hcl | 53 | 18 |
| Midodrine Hcl | Midodrine Hcl | 52 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 51 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 51 | suppressed |
| Fetzima | Levomilnacipran Hcl | 50 | suppressed |
| Topiramate Er | Topiramate | 50 | suppressed |
| Adzenys Xr-Odt | Amphetamine | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 49 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 12 |
| Trileptal | Oxcarbazepine | 49 | suppressed |
| Metformin Hcl | Metformin Hcl | 48 | suppressed |
| Movantik | Naloxegol Oxalate | 48 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 45 | suppressed |
| Nucynta Er | Tapentadol Hcl | 45 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 44 | suppressed |
| Gilenya | Fingolimod Hcl | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 42 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 41 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Fentanyl | Fentanyl | 41 | suppressed |
| Fingolimod | Fingolimod Hcl | 41 | suppressed |
| Fycompa | Perampanel | 41 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 41 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 18 |
| Nourianz | Istradefylline | 41 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 40 | 11 |
| Zonisamide | Zonisamide | 40 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Vimpat | Lacosamide | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 36 | suppressed |
| Buprenorphine | Buprenorphine | 35 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 35 | suppressed |
| Spravato | Esketamine Hcl | 35 | suppressed |
| Vumerity | Diroximel Fumarate | 35 | suppressed |
| Ztlido | Lidocaine | 34 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 33 | suppressed |
| Losartan Potassium | Losartan Potassium | 33 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 32 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 23 |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 31 | suppressed |
| Fluocinonide | Fluocinonide | 30 | suppressed |
| Valtoco | Diazepam | 30 | suppressed |
| Zaleplon | Zaleplon | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Metaxalone | Metaxalone | 29 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 28 | 15 |
| Mavenclad | Cladribine | 28 | 15 |
| Motegrity | Prucalopride Succinate | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Amphetamine Sulfate | Amphetamine Sulfate | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Nystatin | Nystatin | 26 | 11 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 25 | suppressed |
| Gabapentin Er | Gabapentin | 25 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Sunosi | Solriamfetol Hcl | 25 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 24 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 24 | suppressed |
| Lamictal Xr | Lamotrigine | 24 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 24 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 24 | suppressed |
| Tysabri | Natalizumab | 24 | suppressed |
| Gralise | Gabapentin | 23 | suppressed |
| Tecfidera | Dimethyl Fumarate | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 21 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 21 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 21 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 21 | 17 |
| Tascenso Odt | Fingolimod Lauryl Sulfate | 21 | suppressed |
| Copaxone | Glatiramer Acetate | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Relistor | Methylnaltrexone Bromide | 20 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 17 | suppressed |
| Dexilant | Dexlansoprazole | 17 | suppressed |
| Jornay Pm | Methylphenidate Hcl | 17 | suppressed |
| Lyrica | Pregabalin | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Depakote Er | Divalproex Sodium | 16 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Savella | Milnacipran Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Aplenzin | Bupropion Hbr | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Lamictal | Lamotrigine | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Chlorzoxazone | Chlorzoxazone | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Gocovri | Amantadine Hcl | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Pimozide | Pimozide | 13 | suppressed |
| Piroxicam | Piroxicam | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Nitro-Bid | Nitroglycerin | 11 | suppressed |
| Oxcarbazepine Er | Oxcarbazepine | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105,565.30 · 350 records | EMD Serono, Inc. | ACTHAR, Azstarys, BRIUMVI, Bafiertam, Briviact, EPIDIOLEX, FANAPT, FYCOMPA, Fintepla, General - Pain Management, HYQVIA, Hizentra, KESIMPTA, KISUNLA, Leqembi, Mavenclad, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, Radicava, Rystiggo, SKYCLARYS, SPINRAZA, Sunosi, Symbravo, TOLMETIN SODIUM, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYVGART HYTRULO, WAKIX, WaveWriter Alpha Prime 16, Xeomin, ZAVZPRET, ZEPOSIA, ZTLido | 28 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error